Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions. Our latest review on the management of this potentially critical complication and lead by Dr. A. Wonnaparhown (Mayo Clinic

Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. Linda B. Baughn⁩ ⁦Rahul Banerjee, MD, FACP⁩ ⁦Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽⁩ nature.com/articles/s4140…

Major Regulatory Milestone in MM: In response to an application by I2TEAMM and International Myeloma Foundation, the European Medicines Agency has officially endorsed MRD as an early endpoint in clinical trials for Myeloma. This marks a transformative step forward in drug development !! Vincent Rajkumar

#Myeloma Paper of the Day: Patients w/ >8.7 mos between last exposure to prior BCMA-directed therapy & teclistamab have significantly improved median PFS w/ tec (8.1 mos, 95% CI: 4.6-11.7) vs. pts with <8.7 mos (2.5 ms, 95% CI: 1.1-5.7), p=0.001: pubmed.ncbi.nlm.nih.gov/40562770/. #mmsm

This is fantastic news for our CART patients For ide-cel and liso-cel Less driving restrictions : 2 weeks from 8 weeks Less time needed to be at tertiary care center away from home - 2 weeks from 4 weeks Hope we can expand this to other CAR Ts soon #mmsm #lymsm

Extending access for life-saving CAR-T therapies! fda.gov/vaccines-blood…

What’s up with Beta 2 microglobulin (B2M) and myeloma? Why is it the sole non-cytogenetic marker used in the new IMWG high risk definition? Why does it matter whether the creatinine is high or not? Thread 1/

FDA Eliminates REMS for Chimeric Antigen Receptor (CAR) T cell Immunotherapies. Pts now only need to remain close to CAR T facility for 2 weeks (no longer 4 weeks) and avoid driving for 2 weeks (no longer 8 weeks) following CAR T. Huge access improvement! fda.gov/vaccines-blood…

Thank you Robert Z. Orlowski for sharing this collaborative, multi-center #CART consortium paper!! Great work Danai Dima Jack Khouri Faiz Anwer MD Surbhi Sidana, MD et al, who aim to answer important real world sequencing questions! 👏👏

Teclistamamb in RRMM with prior BCMA-directed Rx: Lower ORR (48 vs. 61%) and shorter PFS (4.6 vs. 8.2 months). On MVA, >8.7 month between Tec and prior anti-BCMA Rx had better outcomes #mmsm #bmtsm Danai Dima Leyla Shune MD Blood Cancer Journal nature.com/articles/s4140…

#Myeloma Paper of the Day: Retrospective study of Isa-pom-dex in relapsed/refractory AL #amyloidosis finds overall heme response at 3, 6 & 12 ms was 91.7%, 92%, & 87.5%; median OS & EFS were 53 & 41 mos; 66% of pts achieved best response in 3 mos: pubmed.ncbi.nlm.nih.gov/40605712/. #mmsm

🧵 MAIA Study Update: 5-Year Outcomes in NDMM (Transplant-Ineligible) 📄 Facon et al., Leukemia (2025) 💊 D-Rd = Daratumumab + Lenalidomide + Dexamethasone 👇 For clinicians, here’s what you need to know: 1️⃣ Superior PFS & OS with D-Rd 🛡️ 📈 Median PFS:   • D-Rd: 61.9 mo   •

#Myeloma Paper of the Day: Modification of belantamab mafodotin dosing to balance efficacy and tolerability in DREAMM-7 and DREAMM-8 trials still produced median PFS in patients with ≥1 dose delay of ≥12 weeks of 36.6 months and NR, respectively: pubmed.ncbi.nlm.nih.gov/40763276/. #mmsm

Grateful to all the amazing faculty who’ve joined us in Bermuda this week! 🏝️ #DAVAHeme has been energizing so far, two impactful days of science, collaboration, and big ideas. Can’t wait for three more days of shaping the future of hematologic malignancies care.

Starting Now: Multiple Myeloma: BCMA-targeting Agents Moderated by: Sagar Lonial MD Winship Cancer Institute of Emory University #DAVAHeme

Dr. Jack Khouri presented updates on teclistamab in MM: ✅ Q2W dosing reduces infections ✅ IVIG & dexhelp manage hypogammaglobulinemia & CRS ✅ MajesTEC-4 shows deep responses & high MRD-negativity with fixed-duration maintenance #MultipleMyeloma #DAVAHeme

⁦DAVA Oncology⁩ #DavaHeme MM Bispecific panel